Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), developed to extend the short half-life of native GHRH while preserving its receptor-binding activity. It is one of the more extensively documented GHRH analogs in peptide research literature, with a substantial body of published pharmacokinetic and mechanistic data.
What is Tesamorelin?
Structurally, Tesamorelin is a 44-amino-acid peptide modeled on the first 44 residues of human GHRH, modified with a trans-3-hexenoic acid group at the N-terminus. This modification increases its resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), which otherwise rapidly breaks down native GHRH — a key reason Tesamorelin has become a frequently referenced compound in GHRH stability research.
Mechanism of Action
Like other GHRH analogs, Tesamorelin is studied for its ability to bind GHRH receptors on the anterior pituitary, stimulating the synthesis and pulsatile release of growth hormone. Because it acts upstream of the pituitary's own GH-releasing machinery rather than substituting for GH directly, research on Tesamorelin frequently focuses on how it interacts with the body's natural negative-feedback loop — including somatostatin and insulin-like growth factor 1 (IGF-1) — rather than producing a flat, supraphysiological GH elevation.
Why It's a Frequently Cited Reference Compound
Tesamorelin's well-characterized pharmacokinetic profile — including its half-life, receptor binding affinity, and DPP-4 resistance — has made it a common benchmark compound in comparative GHRH analog research. Studies examining newer GHRH analogs or combination secretagogue protocols frequently reference Tesamorelin's published data as a point of comparison.
Research Applications
● GHRH receptor binding and downstream pituitary signaling
● Pulsatile growth hormone release patterns
● DPP-4 resistance and peptide stability modeling
● Comparative benchmarking against other GHRH analogs and secretagogues
Specifications
|
Classification |
GHRH analog |
|
Structure |
44-amino-acid peptide, N-terminal modified for DPP-4 resistance |
|
Form |
Lyophilized powder, for reconstitution in laboratory settings |
|
Use |
Laboratory and research use only |
This article is intended for scientific and educational purposes only. Tesamorelin is not approved for human or veterinary use and is sold strictly for laboratory research. Nothing in this article should be construed as a recommendation for use outside a controlled research setting.